ABEONA THERAPEUTICS INC. (ABEO) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 17, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for ABEONA THERAPEUTICS INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ABEONA THERAPEUTICS INC.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does ABEONA THERAPEUTICS INC. actually do?
Answer:
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases. In April 2025, the company received FDA approval for ZEVASKYN (prademagene zamikeracel), the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is manufactured at Abeona's cGMP facility in Cleveland, Ohio, and distributed through a network of qualified treatment centers, with four centers activated as of March 2026. The company's pipeline also includes adeno-associated virus (AAV)-based gene therapies targeting ophthalmic diseases, utilizing novel AIMTM capsids for improved tissue targeting. Abeona aims to leverage its manufacturing capabilities and strategic partnerships to advance its portfolio.
Question:
What are ABEONA THERAPEUTICS INC.'s revenue drivers?
Answer:
Revenue is primarily driven by the sale of ZEVASKYN, its first commercial product, and license and other revenues from collaboration and sublicense agreements.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required